Clinical trials: Cocaine
Diagnostic, Procedures and Surgeries on or Through Accessible Mucous Membranes
Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia
This study aims to evaluate topical application of Cocaine HCl 4% and 10% on safety and efficacy in local (topical) anesthesia for diagnostic procedures and surgeries on or through accessible mucous membranes of the nasal…
- Conditions
- Diagnostic, Procedures and Surgeries on or Through Accessible Mucous Membranes, of the Nasal Cavities
- Trial name
- NCT01746940
- Testing
- Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution
- Where
- 2 sites in United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Lannett Company, Inc.
Cocaine Dependency
A Safety, Tolerability and Pharmacokinetic Study of CPP-115
Primary Objective: To evaluate the safety and tolerability of ascending single oral doses of CPP-115 Secondary Objective: To determine the pharmacokinetic profiles of CPP-115 following administration of a ascending single oral…
- Trial name
- NCT01493596
- Testing
- CPP-115
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Cocaine Use Disorder
Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations
This is a study of EMB-001 (a combination of two FDA-approved drugs, metyrapone and oxazepam) in healthy adults.This is a Phase 1, single dose, 3-period, 3-sequence, crossover study in 9 healthy male and female (not of…
- Trial name
- NCT03404817
- Testing
- Original formulation EMB-001, New formulation EMB-001
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Embera NeuroTherapeutics, Inc.
Cocaine Use Disorder
A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only).
- Trial name
- NCT04501874
- Testing
- EMB-001
- Where
- 4 sites in United States
- Volunteers
- 82 people
- Sponsor
- Embera NeuroTherapeutics, Inc.
Stimulant Use Disorder
Smartphone Services for Stimulant Use Disorder
This study is testing two approaches to treating Stimulant Use Disorder, or problems with cocaine, crack, methamphetamine, etc. Stimulant Use Disorder is a national epidemic in the U.S.
- Trial name
- NCT07092059
- Testing
- Smartphone digital therapeutic system
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- DynamiCare Health
Cocaine-related Disorder
Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
This study assessed whether AFQ056 had a beneficial effect by reducing cocaine use in Cocaine Use Disorder (CUD) patients as assessed by Timeline Follow-Back cocaine self-report.
- Trial name
- NCT03242928
- Testing
- AFQ056
- Where
- 8 sites in Argentina, Spain and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Cocaine Use Disorder
A Study to Investigate the Interaction Between TMP-301 and Cocaine.
This will be a randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral TMP-301, given concurrently with cocaine.
- Trial name
- NCT06648668
- Testing
- TMP-301
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Tempero Bio, Inc.
Addiction, Opioid Dependence
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
The purpose of this study is determine the safety, efficacy and tolerability of a novel drug APH-1501 as a pharmacotherapy for Opioid Dependence. The investigators will evaluate the safety of escalating doses APH-1501.
- Conditions
- Addiction, Opioid Dependence, Opioid Withdrawal
- Trial name
- NCT03813095
- Testing
- APH-1501
- Volunteers
- 32 people
- Sponsor
- Aphios